Coronary events are currently the leading cause of death among men and women. In fact, these are often the most common deaths of people in the United States. While most often coronary conditions are treated through lifestyle changes such as ceasing smoking, losing weight, lowering blood pressure, medications or surgeries, other treatments such as oral chelation therapy are on the rise.
The compound used in this therapy has not been reviewed or rated by the U. S. Food and Drug Administration. Regardless, there were over 110,000 Americans whom had previously opted for the treatment prior to a 2007 study. Ultimately, the therapy promotes a chemical process which works to bind molecules to metals and minerals.
The therapy was originally used to eliminate toxic and excess metals from the body. EDTA has had some uses in Western medicine, mostly with regards to iron overload and lead poisoning. Whereas, when used to treat heart disease, a health care provider generally administers a series of injections into the veins over time which include disodium EDTA, a man made amino acid. In most cases, the treatment requires individuals to complete thirty or more infusions which can often take several hours per visit, most often on a weekly basis.
To decipher whether or not this therapy may be effective, the National Center for Complementary and Integrative Health or NCCIH in conjunction with the National Heart, Lung and Blood Institute sponsored a trial with regards to the benefits of these infusions in individuals with a negative cardiovascular medical history. Ultimately, the trial proved that the infusions did in fact provide the most reduction in cardiovascular events, though only in individuals whom also had diabetes.
During the study, individuals with diabetes made up approximately one third of participants. During the trial, diabetics showed a forty one percent reduction in cardiovascular events and a forty percent risk of death from heart disease, stroke or non-fatal heart attacks. In addition, fifty two percent experienced a reduction in repetitive heart attacks and a forty three percent reduction in death from other causes. Whereas, individuals whom did not have diabetes did not experience any significant benefits from the disodium EDTA infusions.
The trial also looked at people taking high dosages of mineral and vitamin supplements in addition to the injections. In most cases, the results showed that the supplements along with the injections reduced the risk of heart attacks in the chelation therapy group versus participants whom were only given placebos.
Over the course of the study, 16% of individuals receiving chelation therapy and 15% of individuals receiving placebos asked to stop the infusions due to adverse effects. Overall, there were four major events, two deaths, one in each the placebo and chelation group and minor side effects. To date, the primary side effect appears to be burning at or near the injection site during the infusion process.
As with most medical studies, additional research is necessary to fully comprehend these results. For, this is the first study to reveal any benefits. As such, the results alone are not enough to support the ongoing routine of chelation therapy as post-heart attack for treatment in people with or without diabetes.
The compound used in this therapy has not been reviewed or rated by the U. S. Food and Drug Administration. Regardless, there were over 110,000 Americans whom had previously opted for the treatment prior to a 2007 study. Ultimately, the therapy promotes a chemical process which works to bind molecules to metals and minerals.
The therapy was originally used to eliminate toxic and excess metals from the body. EDTA has had some uses in Western medicine, mostly with regards to iron overload and lead poisoning. Whereas, when used to treat heart disease, a health care provider generally administers a series of injections into the veins over time which include disodium EDTA, a man made amino acid. In most cases, the treatment requires individuals to complete thirty or more infusions which can often take several hours per visit, most often on a weekly basis.
To decipher whether or not this therapy may be effective, the National Center for Complementary and Integrative Health or NCCIH in conjunction with the National Heart, Lung and Blood Institute sponsored a trial with regards to the benefits of these infusions in individuals with a negative cardiovascular medical history. Ultimately, the trial proved that the infusions did in fact provide the most reduction in cardiovascular events, though only in individuals whom also had diabetes.
During the study, individuals with diabetes made up approximately one third of participants. During the trial, diabetics showed a forty one percent reduction in cardiovascular events and a forty percent risk of death from heart disease, stroke or non-fatal heart attacks. In addition, fifty two percent experienced a reduction in repetitive heart attacks and a forty three percent reduction in death from other causes. Whereas, individuals whom did not have diabetes did not experience any significant benefits from the disodium EDTA infusions.
The trial also looked at people taking high dosages of mineral and vitamin supplements in addition to the injections. In most cases, the results showed that the supplements along with the injections reduced the risk of heart attacks in the chelation therapy group versus participants whom were only given placebos.
Over the course of the study, 16% of individuals receiving chelation therapy and 15% of individuals receiving placebos asked to stop the infusions due to adverse effects. Overall, there were four major events, two deaths, one in each the placebo and chelation group and minor side effects. To date, the primary side effect appears to be burning at or near the injection site during the infusion process.
As with most medical studies, additional research is necessary to fully comprehend these results. For, this is the first study to reveal any benefits. As such, the results alone are not enough to support the ongoing routine of chelation therapy as post-heart attack for treatment in people with or without diabetes.
About the Author:
When you are looking for information about oral chelation, come to our web pages today. More details are available at http://www.heartdrop.com now.
No comments:
Post a Comment